Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron versus haloperidol for prevention of postoperative nausea and vomiting after bilateral mastectomy
IRCT20240224061097N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Haloperidol with Ondansetron (2 arms). Primary endpoint: Incidence of postoperative vomiting. Started Apr 2024; status: completed.
02
Drugs
ondansetronhaloperidol
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on IRCT20240224061097N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240224061097N1.